Trial Profile
A phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding trial to evaluate the efficacy and safety of IMU-838 for treatment of patients with active Crohn's disease with an option for open-label treatment extension (CALDOSE-2)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2022
Price :
$35
*
At a glance
- Drugs Vidofludimus calcium (Primary)
- Indications Crohn's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms CALDOSE-2
- Sponsors Immunic
- 30 Jul 2022 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.
- 29 Jul 2022 This trial has been discontinued in Bulgaria and Netherlands, according to European Clinical Trials Database record.
- 15 Jul 2022 This trial has been completed in Croatia, according to European Clinical Trials Database record.